ArticlesIncreased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
References (30)
Pulmonary embolism
Lancet
(1961)Thrombophilia: the new factor is old factor V
Lancet
(1994)- et al.
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
Lancet
(1993) - et al.
APC-resistance as an additional risk factor for thrombosis in protein C deficient families
Blood
(1994) Oral contraceptives and cardiovascular disease (first of two parts)
N Engl J Med
(1981)- et al.
Oral contraceptives and cardiovascular disease
Epidemiol Rev
(1982) - et al.
Oral contraceptives and nonfatal vascular disease: recent experience
Obstet Gynecol
(1982) - et al.
Oral contraceptives and nonfatal vascular disease
Obstet Gynecol
(1985) - et al.
Oral contraceptives and venous thromboembolism: findings in a large prospective study
BMJ
(1986) - et al.
Venous thromboembolism in relation to oral contraceptive use
Obstet Gynecol
(1987)
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
Am J Epidemiol
(1991)
Familial thrombophilia due to a previously unecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
Proc Natl Acad Sci USA
(1993)
Mutation in blood coagulation factor V associated with resistance to activated protein C
Nature
(1994)
Evaluation of activated protein C resistance in stored plasma
Lancet
(1994)
Cited by (1138)
The risk of venous thromboembolism in oral contraceptive users: the role of genetic factors—a prospective cohort study of 240,000 women in the UK Biobank
2024, American Journal of Obstetrics and GynecologyHemostatic considerations for gender affirming care
2023, Thrombosis ResearchDisorders of Hemostasis and Thrombosis
2022, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Hematologic, Renal, and Immunologic Disorders
Copyright © 1994 Published by Elsevier Ltd.